Most importantly, pharmacological inhibition of the TGFβ-SMAD3 pathway was sufficient to drive Ahr-deficient CPCs towards differentiation, identifying this pathway as a potentially viable therapeutic target for aggressive medulloblastoma subtypes with reduced AHR pathway activity and elevated TGFβ-SMAD3 signalling. This evidence concerns the gene SMAD3 and medulloblastoma.